FDA grants priority review to supplemental new drug application for osimertinib as adjuvant treatment of early stage (Ib, II, IIIA) EGFR-mutated non-small cell lung cancer after complete tumour resection with curative intent

Application is based on results from the ADAURA phase III trial, which demonstrated statistically significant improvement in disease-free survival in the primary analysis population of patients with stage II and IIa EGFR-mutated non-small cell lung cancer.

Source:

PharmaTimes